Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Nurix Therapeutics, Inc. (NRIX) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Nurix Therapeutics, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1549595.
Total stock buying since 2020: $0.
Total stock sales since 2020: $13,353,847.
Total stock option exercises since 2020: $1,215,172.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 0 | $0 | 177,548 | $3,425,626 | 178,811 | $387,662 |
| 2025 | 0 | $0 | 112,573 | $1,705,143 | 197,585 | $147,627 |
| 2024 | 0 | $0 | 145,484 | $3,072,961 | 133,741 | $235,375 |
| 2023 | 0 | $0 | 29,430 | $279,883 | 45,991 | $0 |
| 2022 | 0 | $0 | 11,772 | $203,366 | 98,297 | $75,013 |
| 2021 | 0 | $0 | 134,032 | $4,666,868 | 134,032 | $359,415 |
| 2020 | 0 | $0 | 0 | $0 | 12,000 | $10,080 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-04-30 | Wolff Stefani (EVP and COO) | Option Ex | 962 | .00 | 0 |
| 2023-01-30 | Van Houte Hans (Chief Financial Officer) | Sale | 924 | 11.78 | 10,884 |
| 2023-01-30 | Van Houte Hans (Chief Financial Officer) | Option Ex | 2,886 | .00 | 0 |
| 2023-01-30 | Ring Christine (General Counsel) | Sale | 848 | 11.78 | 9,989 |
| 2023-01-30 | Ring Christine (General Counsel) | Option Ex | 1,924 | .00 | 0 |
| 2023-01-30 | Hansen Gwenn (Chief Scientific Officer) | Sale | 1,412 | 11.78 | 16,633 |
| 2023-01-30 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 3,207 | .00 | 0 |
| 2023-01-30 | Wolff Stefani (EVP and COO) | Sale | 424 | 11.78 | 4,994 |
| 2023-01-30 | Wolff Stefani (EVP and COO) | Option Ex | 962 | .00 | 0 |
| 2022-10-31 | Van Houte Hans (Chief Financial Officer) | Sale | 739 | 12.88 | 9,519 |
| 2022-10-31 | Ring Christine (General Counsel) | Sale | 699 | 12.88 | 9,003 |
| 2022-10-31 | Hansen Gwenn (Chief Scientific Officer) | Sale | 1,165 | 12.88 | 15,006 |
| 2022-10-31 | Wolff Stefani (EVP and COO) | Sale | 350 | 12.88 | 4,508 |
| 2022-10-30 | Van Houte Hans (Chief Financial Officer) | Option Ex | 2,886 | .00 | 0 |
| 2022-10-30 | Ring Christine (General Counsel) | Option Ex | 1,924 | .00 | 0 |
| 2022-10-30 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 3,207 | .00 | 0 |
| 2022-10-30 | Wolff Stefani (EVP and COO) | Option Ex | 962 | .00 | 0 |
| 2022-08-01 | Van Houte Hans (Chief Financial Officer) | Sale | 752 | 15.67 | 11,783 |
| 2022-08-01 | Ring Christine (General Counsel) | Sale | 712 | 15.67 | 11,157 |
| 2022-08-01 | Hansen Gwenn (Chief Scientific Officer) | Sale | 1,186 | 15.67 | 18,584 |
| 2022-08-01 | Wolff Stefani (EVP and COO) | Sale | 356 | 15.67 | 5,578 |
| 2022-07-30 | Van Houte Hans (Chief Financial Officer) | Option Ex | 2,886 | .00 | 0 |
| 2022-07-30 | Ring Christine (General Counsel) | Option Ex | 1,924 | .00 | 0 |
| 2022-07-30 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 3,207 | .00 | 0 |
| 2022-07-30 | Wolff Stefani (EVP and COO) | Option Ex | 962 | .00 | 0 |
| 2022-05-31 | Van Houte Hans (Chief Financial Officer) | Option Ex | 68,333 | .84 | 57,399 |
| 2022-05-02 | Van Houte Hans (Chief Financial Officer) | Sale | 697 | 11.75 | 8,189 |
| 2022-05-02 | Ring Christine (General Counsel) | Sale | 660 | 11.75 | 7,755 |
| 2022-05-02 | Hansen Gwenn (Chief Scientific Officer) | Sale | 1,098 | 11.75 | 12,901 |
| 2022-05-02 | Wolff Stefani (EVP and COO) | Sale | 330 | 11.75 | 3,877 |
| 2022-04-30 | Van Houte Hans (Chief Financial Officer) | Option Ex | 2,886 | .00 | 0 |
| 2022-04-30 | Ring Christine (General Counsel) | Option Ex | 1,924 | .00 | 0 |
| 2022-04-30 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 3,206 | .00 | 0 |
| 2022-04-30 | Wolff Stefani (EVP and COO) | Option Ex | 962 | .00 | 0 |
| 2022-01-10 | Ring Christine (General Counsel) | Sale | 1,200 | 27.14 | 32,568 |
| 2022-01-10 | Ring Christine (General Counsel) | Option Ex | 1,200 | 1.86 | 2,232 |
| 2022-01-03 | Hansen Gwenn (Chief Scientific Officer) | Sale | 1,828 | 28.96 | 52,938 |
| 2022-01-03 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 1,828 | 8.41 | 15,382 |
| 2021-12-10 | Ring Christine (General Counsel) | Sale | 1,200 | 29.04 | 34,848 |
| 2021-12-10 | Ring Christine (General Counsel) | Option Ex | 1,200 | 1.86 | 2,232 |
| 2021-12-01 | Hansen Gwenn (Chief Scientific Officer) | Sale | 400 | 29.13 | 11,652 |
| 2021-12-01 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 400 | 7.26 | 2,904 |
| 2021-11-10 | Ring Christine (General Counsel) | Sale | 1,200 | 32.38 | 38,856 |
| 2021-11-10 | Ring Christine (General Counsel) | Option Ex | 1,200 | 1.86 | 2,232 |
| 2021-11-01 | Hansen Gwenn (Chief Scientific Officer) | Sale | 400 | 33.24 | 13,296 |
| 2021-11-01 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 400 | 7.26 | 2,904 |
| 2021-10-27 | Ring Christine (General Counsel) | Sale | 800 | 35.25 | 28,200 |
| 2021-10-27 | Ring Christine (General Counsel) | Option Ex | 800 | 1.86 | 1,488 |
| 2021-10-27 | Hansen Gwenn (Chief Scientific Officer) | Sale | 400 | 35.00 | 14,000 |
| 2021-10-27 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 400 | 7.26 | 2,904 |
| 2021-10-11 | Ring Christine (General Counsel) | Sale | 1,200 | 27.36 | 32,832 |
| 2021-10-11 | Ring Christine (General Counsel) | Option Ex | 1,200 | 1.86 | 2,232 |
| 2021-10-01 | Hansen Gwenn (Chief Scientific Officer) | Sale | 400 | 29.92 | 11,968 |
| 2021-10-01 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 400 | 7.26 | 2,904 |
| 2021-09-10 | Ring Christine (General Counsel) | Sale | 2,000 | 35.88 | 71,750 |
| 2021-09-10 | Ring Christine (General Counsel) | Option Ex | 2,000 | 1.86 | 3,720 |
| 2021-09-07 | Ring Christine (General Counsel) | Sale | 3,200 | 35.25 | 112,800 |
| 2021-09-07 | Ring Christine (General Counsel) | Option Ex | 3,200 | 1.86 | 5,952 |
| 2021-09-07 | Hansen Gwenn (Chief Scientific Officer) | Sale | 1,600 | 35.00 | 56,000 |
| 2021-09-07 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 1,600 | 7.26 | 11,616 |
| 2021-09-01 | Hansen Gwenn (Chief Scientific Officer) | Sale | 400 | 32.34 | 12,936 |
| 2021-09-01 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 400 | 7.26 | 2,904 |
| 2021-08-10 | Beaurang Pierre (Chief Business Officer) | Sale | 7,500 | 29.98 | 224,812 |
| 2021-08-10 | Beaurang Pierre (Chief Business Officer) | Option Ex | 7,500 | 1.11 | 8,325 |
| 2021-08-10 | Ring Christine (General Counsel) | Sale | 1,200 | 29.87 | 35,845 |
| 2021-08-10 | Ring Christine (General Counsel) | Option Ex | 1,200 | 1.86 | 2,232 |
| 2021-08-02 | Hansen Gwenn (Chief Scientific Officer) | Sale | 400 | 31.21 | 12,484 |
| 2021-08-02 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 400 | 7.26 | 2,904 |
| 2021-07-20 | Ring Christine (General Counsel) | Sale | 1,200 | 27.00 | 32,400 |
| 2021-07-20 | Ring Christine (General Counsel) | Option Ex | 1,200 | 1.86 | 2,232 |
| 2021-07-12 | Beaurang Pierre (Chief Business Officer) | Sale | 7,500 | 24.30 | 182,280 |
| 2021-07-12 | Beaurang Pierre (Chief Business Officer) | Option Ex | 7,500 | 1.11 | 8,325 |
| 2021-06-01 | Hansen Gwenn (Chief Scientific Officer) | Sale | 400 | 27.74 | 11,096 |
| 2021-06-01 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 400 | 7.26 | 2,904 |
| 2021-05-10 | Beaurang Pierre (Chief Business Officer) | Sale | 7,500 | 26.87 | 201,510 |
| 2021-05-10 | Beaurang Pierre (Chief Business Officer) | Option Ex | 7,500 | 1.11 | 8,325 |
| 2021-05-10 | Ring Christine (General Counsel) | Sale | 1,200 | 27.00 | 32,400 |
| 2021-05-10 | Ring Christine (General Counsel) | Option Ex | 1,200 | 1.86 | 2,232 |
| 2021-05-03 | Hansen Gwenn (Chief Scientific Officer) | Sale | 800 | 34.99 | 27,995 |
| 2021-05-03 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 800 | 7.26 | 5,808 |
| 2021-04-28 | Ring Christine (General Counsel) | Sale | 800 | 35.25 | 28,200 |
| 2021-04-28 | Ring Christine (General Counsel) | Option Ex | 800 | 1.86 | 1,488 |
| 2021-04-12 | Beaurang Pierre (Chief Business Officer) | Sale | 7,500 | 27.72 | 207,877 |
| 2021-04-12 | Beaurang Pierre (Chief Business Officer) | Option Ex | 7,500 | .97 | 7,312 |
| 2021-04-12 | Ring Christine (General Counsel) | Sale | 1,200 | 27.20 | 32,640 |
| 2021-04-12 | Ring Christine (General Counsel) | Option Ex | 1,200 | 1.86 | 2,232 |
| 2021-04-01 | Hansen Gwenn (Chief Scientific Officer) | Sale | 400 | 31.55 | 12,620 |
| 2021-04-01 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 400 | 7.26 | 2,904 |
| 2021-03-16 | Hansen Gwenn (Chief Scientific Officer) | Sale | 800 | 45.00 | 36,000 |
| 2021-03-16 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 800 | 7.26 | 5,808 |
| 2021-03-10 | Ring Christine (General Counsel) | Sale | 2,000 | 41.84 | 83,674 |
| 2021-03-10 | Ring Christine (General Counsel) | Option Ex | 2,000 | 1.86 | 3,720 |
| 2021-03-08 | Beaurang Pierre (Chief Business Officer) | Sale | 7,500 | 37.38 | 280,312 |
| 2021-03-08 | Beaurang Pierre (Chief Business Officer) | Option Ex | 7,500 | .84 | 6,300 |
| 2021-03-01 | Hansen Gwenn (Chief Scientific Officer) | Sale | 800 | 35.95 | 28,760 |
| 2021-03-01 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 800 | 7.26 | 5,808 |
| 2021-02-24 | Van Houte Hans (Chief Financial Officer) | Sale | 35,419 | 39.90 | 1,413,218 |
| 2021-02-24 | Van Houte Hans (Chief Financial Officer) | Option Ex | 35,419 | 3.44 | 121,841 |
| 2021-02-22 | Van Houte Hans (Chief Financial Officer) | Sale | 5,330 | 39.93 | 212,837 |
| 2021-02-22 | Van Houte Hans (Chief Financial Officer) | Option Ex | 5,330 | 1.02 | 5,436 |
| 2021-02-18 | Beaurang Pierre (Chief Business Officer) | Sale | 15,000 | 36.00 | 540,000 |
| 2021-02-18 | Beaurang Pierre (Chief Business Officer) | Option Ex | 15,000 | 5.89 | 88,350 |
| 2021-02-18 | Van Houte Hans (Chief Financial Officer) | Sale | 13,583 | 36.06 | 489,802 |
| 2021-02-18 | Van Houte Hans (Chief Financial Officer) | Option Ex | 13,583 | .84 | 11,409 |
| 2021-02-18 | Ring Christine (General Counsel) | Sale | 2,000 | 35.79 | 71,578 |
| 2021-02-18 | Ring Christine (General Counsel) | Option Ex | 2,000 | 1.86 | 3,720 |
| 2021-02-18 | Hansen Gwenn (Chief Scientific Officer) | Sale | 800 | 36.74 | 29,390 |
| 2021-02-18 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 800 | 7.26 | 5,808 |
| 2020-11-30 | Hansen Gwenn (Chief Scientific Officer) | Option Ex | 12,000 | .84 | 10,080 |
Insider trading activities including stock purchases, stock sales, and option exercises of NRIX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Nurix Therapeutics, Inc. (symbol NRIX, CIK number 1549595) see the Securities and Exchange Commission (SEC) website.